about
A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis CNon-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional studyIdentification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohortRelationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.Role of cytokine gene polymorphisms in acute rejection and renal impairment after liver transplantation.Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkersMultimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trialLow density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase gene expression in human mononuclear leukocytes is regulated coordinately and parallels gene expression in human liverAdiponectin and its receptors in patients with chronic hepatitis C.Senescent human hepatocytes express a unique secretory phenotype and promote macrophage migrationInteraction of non-alcoholic fatty liver disease with other liver diseases.Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease.Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease.Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C.Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of lifeNonalcoholic fatty liver disease: is all the fat bad?Macrophage secretory products induce an inflammatory phenotype in hepatocytesAltered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation.Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.Deletion of Wntless in myeloid cells exacerbates liver fibrosis and the ductular reaction in chronic liver injury.Steatosis: co-factor in other liver diseases.Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established BiomarkersCan paracetamol (acetaminophen) be administered to patients with liver impairment?Steatosis as a cofactor in other liver diseases: hepatitis C virus, alcohol, hemochromatosis, and others.Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.Triage of referrals to outpatient hepatology services: an ineffective tool to prioritise patients?BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin.Burden of decompensated cirrhosis and ascites on hospital services in a tertiary care facility: time for change?The Enhanced liver fibrosis score is associated with clinical outcomes and disease progression in patients with chronic liver disease.The toll-like receptor 3 pathway in homeostasis, responses to injury and wound repair.Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia.Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease.Identifying areas of need relative to liver disease: geographic clustering within a health service district.Interleukin-32: a new proinflammatory cytokine involved in hepatitis C virus-related liver inflammation and fibrosis.Liver-related mortality in countries of the developed world: an ecological study approach to explain the variability.
P50
Q27477866-D7B6B3D9-BB9A-4382-AD7F-987EAFC118F8Q27478313-64903296-6AB0-486F-92BF-6CCFE5553FFDQ28477057-6D605DD1-7034-4693-B0BB-A903E9C6E1F1Q28478435-00A2468D-EAB8-4FD8-B000-8B440F9EE2FCQ31040495-C69D55BD-A3E3-4E08-B945-6BE7BB995EB8Q32186756-613FB4D3-039E-4BFC-8AE0-901BD0473A20Q33701694-52521E1C-19B5-42F2-800A-08C6920C57E2Q33879548-305FF2FB-9E43-4600-97CC-3E77E89BAE17Q33921869-89FFB0CE-0246-4FD8-B3AA-DA7B20EA6BA2Q34146022-5A2CBC0B-7D7A-4883-B0E6-CE487643C736Q34448049-3091C4F3-6A58-499F-8F48-A52A2949385CQ34750592-BBDC144A-72AA-4AB6-8FD7-BC65ADA85941Q34983530-3BC8ECE0-EB0C-430A-90CD-00115252D9B6Q35189328-2867BD97-B7B4-4A8E-BFB6-2E06F5396A32Q35197060-92E9206B-7D37-4052-92B0-9A21861A6601Q35332315-CF810B49-9307-48E0-831A-F602F2AD4EE7Q35594723-F4AC0EB5-D367-4385-9120-319AAACFAE59Q35596306-984BEBA1-65C2-4B0E-9685-93728F03F1AEQ35746690-8CAD7A9C-D914-4EC2-9F0C-1D9EC38E5E66Q35904291-731D4A8D-099D-4106-890C-2471A7D9E299Q36054086-DD933867-0F28-4630-97E4-19605AD07AA1Q36130230-509882C8-26A0-4A2B-9B50-DB24FE71C8D9Q36163662-DFBEB6F2-5852-4C42-B73B-E2B99B375F5EQ36165987-125F4A4B-F97A-4A80-A6E9-62706C3D1043Q36197398-EC2A4FFC-D3C7-4697-9E44-8278DADAFD60Q36802077-0A0196BF-0147-4FD5-A0AE-728DEA6ED677Q36838605-D1F54139-6A57-445E-B0EA-EB2CDB37937CQ37225844-BFF338FF-034A-4C8D-BF4B-1ED84D3B8C20Q37264708-ECCDAD0B-7B7D-49D0-A717-B7E53EBB1B07Q38051833-80DC4617-6EE8-434D-964F-6E3AF1EEB00DQ38123193-39DCBB96-8708-46E1-AF59-B62FAB17C7A7Q38217349-E6D84510-12FB-4A54-9C16-C609622A43D4Q38535634-0A80C808-1C63-4F9B-AB43-C5D7C622443EQ38828630-104EF5C5-8DC1-43F1-A831-1C73524A7162Q38987559-8615F686-CA49-488A-9D48-717AA622500EQ39043874-466761DC-8274-463A-A9EA-E9C3B11D48EFQ39311652-15F1A0B7-A8A0-44B9-8702-B421990D0027Q39504476-9327A4C7-C75B-4108-8FC4-A42C7909F590Q39580319-9E4ED118-567F-437A-A9D5-EC7E7C935BAFQ39758401-65940227-2950-4363-B529-5D36343FAC94
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Elizabeth Powell
@ast
Elizabeth Powell
@en
Elizabeth Powell
@es
Elizabeth Powell
@nl
Elizabeth Powell
@sl
Елизавета Пауэлл
@ru
إليزابيث باول
@ar
type
label
Elizabeth Powell
@ast
Elizabeth Powell
@en
Elizabeth Powell
@es
Elizabeth Powell
@nl
Elizabeth Powell
@sl
Елизавета Пауэлл
@ru
إليزابيث باول
@ar
prefLabel
Elizabeth Powell
@ast
Elizabeth Powell
@en
Elizabeth Powell
@es
Elizabeth Powell
@nl
Elizabeth Powell
@sl
Елизавета Пауэлл
@ru
إليزابيث باول
@ar
P1053
B-4455-2011
P106
P1153
7102407844
P21
P31
P3829
P496
0000-0001-5008-8061